{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-015897","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2022-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.702482+00:00","generated_at":"2026-06-25T05:25:39.034270+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Esperion appoints J. Martin Carroll as Chairperson of the Board and new director","bullets":["J. Martin Carroll appointed to fill newly created vacancy; board expands from 9 to 10 directors.","Carroll named Chairperson of the Board effective June 1, 2022.","Carroll previously served as President/CEO of Boehringer Ingelheim Corporation and Merck & Co. veteran.","Esperion reiterates expectation for CLEAR Outcomes topline data in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-015897","json":"https://secwatch.observer/filing/0001628280-22-015897.json","markdown":"https://secwatch.observer/filing/0001628280-22-015897.md","text":"https://secwatch.observer/filing/0001628280-22-015897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/0001628280-22-015897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/espr-20220601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:25:39.034270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"219c2f0334","claim":"J. Martin Carroll was appointed as Chairperson of the Board at Esperion Therapeutics, Inc..","evidence_excerpt":"On June 1, 2022, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) elected J. Martin Carroll to fill in the newly created vacancy on the Board resulting from an increase in the size of the Board from nine (9) directors to ten (10) directors, effective June 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/0001628280-22-015897-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}